This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Alec Machiels Biography and Net Worth

Director of Apellis Pharmaceuticals

Alec Machiels is the Founder and Managing Partner of CoLift, a new private equity platform bringing together a global network of leaders with bespoke investment opportunities. He was a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager with approximately $2bn in assets under management. Mr. Machiels was a member of the firm’s executive and investment committees. He has over 20 years of private equity investing and investment banking experience. Previously, Mr. Machiels was a financial analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs & Co. in New York. Investments in which he has been highly involved include Pure Biofuel, Molycorp Minerals, Traxys, Slipstream Communications, Coffeyville Resources, and Merisant Company. He also co-founded and serves as a board member of Potentia Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. which respectively have drugs in Phase III development to treat macular degeneration and rare diseases. He also served as a member of the board of trustees of the American Federation of Arts, where he chaired the endowment committee. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium, and Konstanz University in Germany.

What is Alec Machiels' net worth?: The estimated net worth of Alec Machiels is at least $10.10 million as of November 17th, 2023. Mr. Machiels owns 367,420 shares of Apellis Pharmaceuticals stock worth more than $10,100,376 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Machiels may own. Additionally, Mr. Machiels receives a salary of $90,620.00 as Director at Apellis Pharmaceuticals. Learn More about Alec Machiels' net worth.
How old is Alec Machiels?: Mr. Machiels is currently 51 years old. There are 6 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corporate Controller & Chief Accounting Officer, who is 57 years old. Learn More on Alec Machiels' age.
What is Alec Machiels' salary?: As the Director of Apellis Pharmaceuticals, Inc., Mr. Machiels earns $90,620.00 per year. There are 6 executives that earn more than Mr. Machiels. The highest earning executive at Apellis Pharmaceuticals is Dr. Cedric Francois M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,440,000.00 per year. Learn More on Alec Machiels' salary.
How do I contact Alec Machiels?: The corporate mailing address for Mr. Machiels and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Alec Machiels' contact information.
Has Alec Machiels been buying or selling shares of Apellis Pharmaceuticals?: Alec Machiels has not been actively trading shares of Apellis Pharmaceuticals during the last ninety days. Most recently, Alec Machiels sold 1,250 shares of the business's stock in a transaction on Friday, November 17th. The shares were sold at an average price of $47.74, for a transaction totalling $59,675.00. Following the completion of the sale, the director now directly owns 367,420 shares of the company's stock, valued at $17,540,630.80. Learn More on Alec Machiels' trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 33 times. They sold a total of 596,910 shares worth more than $33,545,080.32. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 9/16/2024.

Alec Machiels Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2023	Sell	1,250	$47.74	$59,675.00	367,420
10/17/2023	Sell	1,250	$48.50	$60,625.00	367,420
9/18/2023	Sell	1,250	$45.00	$56,250.00	367,420
9/15/2023	Sell	1,250	$45.34	$56,675.00	367,420
7/17/2023	Sell	1,250	$64.79	$80,987.50	267,641
6/20/2023	Sell	1,250	$88.41	$110,512.50	267,641
5/17/2023	Sell	1,250	$88.66	$110,825.00	267,641
4/17/2023	Sell	1,250	$81.05	$101,312.50	267,641
3/17/2023	Sell	1,250	$64.03	$80,037.50	267,641
1/17/2023	Sell	1,250	$52.42	$65,525.00	267,641
12/15/2022	Sell	1,250	$52.35	$65,437.50	263,774
10/14/2022	Sell	1,250	$59.31	$74,137.50	263,774
9/15/2022	Sell	1,250	$66.00	$82,500.00	263,774
8/15/2022	Sell	1,250	$67.21	$84,012.50	263,774
7/15/2022	Sell	1,250	$46.33	$57,912.50	263,774
6/15/2022	Sell	1,250	$39.29	$49,112.50	263,774
5/16/2022	Sell	1,250	$39.18	$48,975.00	263,774
4/14/2022	Sell	1,250	$50.90	$63,625.00	263,774
3/15/2022	Sell	1,250	$39.57	$49,462.50
2/15/2022	Sell	1,250	$45.43	$56,787.50
1/14/2022	Sell	1,250	$40.56	$50,700.00
7/15/2021	Sell	2,500	$62.30	$155,750.00	672,044
6/15/2021	Sell	2,500	$64.83	$162,075.00	672,044
4/21/2021	Sell	2,500	$45.76	$114,400.00	672,044
3/15/2021	Sell	2,500	$46.77	$116,925.00	672,044
1/15/2021	Sell	2,500	$53.15	$132,875.00	672,044
11/16/2020	Sell	2,500	$39.38	$98,450.00	672,044
10/15/2020	Sell	2,500	$35.00	$87,500.00	672,044
10/7/2020	Sell	7,500	$35.00	$262,500.00	677,044
6/15/2020	Sell	2,500	$30.21	$75,525.00

Alec Machiels Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $27.07

$26.90

$27.45

50 Day Range

MA: $29.45

$26.18

$38.36

2 Week Range

Now: $27.07

$24.34

$73.80

Volume

80,269 shs

Average Volume

1,894,124 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

This Bull Market Indicator called NVDA at $116

From WealthPress | Ad

All you have to do is follow this link here

Alec Machiels Biography and Net Worth

What is Alec Machiels' net worth?

How old is Alec Machiels?

What is Alec Machiels' salary?

How do I contact Alec Machiels?

Has Alec Machiels been buying or selling shares of Apellis Pharmaceuticals?

Who are Apellis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Apellis Pharmaceuticals?